Syros Pharmaceuticals

January 28, 2020February 3, 2020

First Patient Dosed in Phase 1 Trial of SY-5609 for OC, Other Solid Tumors, Syros Announces

News

Syros Pharmaceuticals announced the dosing of the first patient in its Phase 1 trial of SY-5609, an investigational oral medication for ovarian cancer and other types of solid tumors. The ... Read more

November 6, 2019

Syros’ SY-5609 Shows Promising Activity in OC Models, Supports Planned Phase 1 Trial, Results Show

News

Syros Pharmaceuticals‘ investigational oral inhibitor, SY-5609, can lead to a sustained inhibition of cancer growth in animal models of ovarian cancer and other solid tumors, preclinical data showed. The findings ... Read more

May 17, 2017

First Patient Dosed in Syros’ Phase 1 Trial for Ovarian, Other Solid Tumors

News

The first patient has been dosed in a Phase 1 trial assessing Syros Pharmaceuticals‘ investigative therapy SY-1365 in patients with advanced solid tumors, the company announced. The trial will particularly ... Read more

April 17, 2017April 17, 2017

Syros’ SY-1365 Displays Punch Against Ovarian Cancer, Studies Show

News

Syros Pharmaceuticals’ investigational compound SY-1365 showed potent anticancer activity in cell and animal models of ovarian cancer, giving the company momentum to move toward the Phase 1 trial it plans later ... Read more